Ionis Pharmaceuticals (IONS) Cash & Current Investments (2009 - 2026)

Ionis Pharmaceuticals' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $1.9 billion for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 10.54% year-over-year to $1.9 billion in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 10.54% decrease from a year earlier, with the FY2025 full-year figure at $2.7 billion, up 16.53% from the prior year.
• Cash & Current Investments retreated to $1.9 billion in Q1 2026 per IONS's latest filing, from $2.7 billion in the prior quarter.
• Across five years, Cash & Current Investments topped out at $2.7 billion in Q4 2025 and bottomed at $1.9 billion in Q1 2026.
• The 5-year median for Cash & Current Investments is $2.2 billion (2023), against an average of $2.2 billion.
• Across the five-year window, Cash & Current Investments increased 17.98% in 2023 and decreased 12.86% in 2024, its largest moves.
• Year by year, Cash & Current Investments stood at $2.0 billion in 2022, then grew by 17.33% to $2.3 billion in 2023, then dropped by 1.44% to $2.3 billion in 2024, then advanced by 16.53% to $2.7 billion in 2025, then slipped by 28.32% to $1.9 billion in 2026.
• Per Business Quant, the three latest IONS Cash & Current Investments figures stand at $1.9 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.2 billion (Q3 2025).